Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
.... surprised by the sp at CoP today. I think awareness of the accuracy and subsequently effect of the PSE test and what it will do for both patients and health institutions is gathering pace both in the US and EU. Hopefully in the coming weeks and months that will be reflected in the sp being way north of today,s closing price.
...demand for PSE blood test after announcement of its high accuracy performance led the group to accelerate its development.........we continue to focus commercially on growing CIRT sales and establishing the revenue engine......"
Quote from CEO earlier this year.
Interesting to see if an RNS drops Monday........two weeks since launch of test.......one week since reimbursement code issued............could we get update on number of enquiries / sales...........OBD seem to be the informative type..........could be fireworks......π
If history is about to repeat itself.............press quote from Jan 2018............."Announcements have gushed out of the press office of genetics specialist Oxford BioDynamics (OBD) in the last six months and investors have started to take notice. The shares hit a record high of 279p in October after the groupβs proprietary biotechnology platform EpiSwitch was successful is diagnosing breast cancer, earned patent approval in the US, and began to generate commercial interest in Asia. Recently signed partnerships with two major US pharma companies have created optimism that OBD and EpiSwitch could play an important role in the future of personalised medicine"...................hmmmm π°
Exactly.......seems to a number of uses for this EpiSwitch tech.......PSE being only one of them......a modest 500 tests per day @ a conservative Β£300 for PSE alone brings in almost Β£55m annually........scale that up in test numbers/price/additional areas of usage.........π°
The RNS is quite clear to me.......or is there something I am not seeing..........."Coinciding with Prostate Cancer Awareness month, OBD has brought forward the launch of its highly accurate, 94% precision medicine test to make it immediately available to men being screened for prostate cancer. This includes those who have received an elevated prostate-specific antigen (PSA) result as well as many others where prostate cancer is a clinical concern."......................... IMMEDIATELY AVAILABLE